Enhanced Therapeutic Approaches for Hearing Loss Prevention and Treatment

This inventive concept builds upon the original patent by introducing novel combinations, formulations, and delivery systems to improve the prevention and treatment of hearing loss caused by chemotherapy or noise exposure.

The original patent addressed the need for therapeutic uses of compounds for treating, inhibiting, and/or preventing loss of hearing. However, the original method had limitations, such as potential reduced efficacy due to inadequate bioavailability or short duration of action. The new inventive concept solves these problems by introducing enhancements that improve the protective effects on inner ear cells, prolong the duration of action, and reduce inflammation.

The new inventive concept comprises four main aspects: (1) a system for treating hearing loss using a combination of chaetocin and a second therapeutic agent, (2) a method for preventing hearing loss caused by chemotherapy using a sustained release formulation of chaetocin, (3) a composition for treating hearing loss that enhances the bioavailability of chaetocin in the inner ear, and (4) a device for delivering a hearing loss treatment using a cochlear implant and a reservoir for storing and releasing the combination of chaetocin and a second therapeutic agent. These enhancements improve the efficacy and safety of the original method.

The new claims introduce novel combinations, formulations, and delivery systems that are not obvious from the original patent. Specifically, the use of a second therapeutic agent, sustained release formulations, and cochlear implants with reservoirs are new and non-obvious features that improve the original method.

Alternative embodiments of the inventive concept could include using different second therapeutic agents, varying the ratio of chaetocin to the second agent, or using different delivery systems such as nanoparticles or liposomes. Variations of the composition could include using different solvents or excipients to enhance bioavailability.

The enhanced therapeutic approaches for hearing loss prevention and treatment have significant commercial potential in the pharmaceutical and medical device industries. The target market includes cancer patients undergoing chemotherapy, individuals exposed to loud noise, and those with existing hearing loss.